Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer

S Crippa, Roberto Cirocchi, P Maisonneuve, S Partelli, I Pergolini, D Tamburrino, F Aleotti, M Reni, M Falconi

Research output: Contribution to journalArticle

Abstract

Background: Identification of factors associated with dismal survival after surgery in resectable pancreatic ductal adenocarcinoma is important to select patients for neoadjuvant treatment. The present meta-analysis aimed to compare the results of distal pancreatectomy for resectable adenocarcinoma of the pancreatic body-tail with and without splenic vessels infiltration. Methods: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines. The inclusion criteria were studies including patients who underwent distal pancreatectomy for pancreatic cancer with or without splenic vessels infiltration. 5-year overall survival (OS) was the primary outcomes. Meta-analysis was carried out applying time-to-event method. Results: Six articles with 423 patients were analysed. Patients with pathological splenic artery invasion had a worse survival compared with those without infiltration (Hazard ratio 1.76, 95% CI 1.36-2.28; P < 0.0001). A similar results was found when considering pathological splenic vessels infiltration, showing that survival was significantly poorer when splenic vein infiltration was present (Hazard ratio 1.51, 95% CI 1.19-1.93; P = 0.0009). Conclusions: This meta-analysis showed worse survival for patients with splenic vessels infiltration undergoing distal pancreatectomy for pancreatic cancer. Splenic vessels infiltration represents the stigmata of a more aggressive disease, although resectable. © 2017 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology.
Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Pancreatic Neoplasms
Meta-Analysis
Pancreatectomy
Survival
Adenocarcinoma
Splenic Vein
Splenic Artery
Christianity
Neoadjuvant Therapy
PubMed
Libraries
Guidelines

Cite this

Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. / Crippa, S; Cirocchi, Roberto; Maisonneuve, P; Partelli, S; Pergolini, I; Tamburrino, D; Aleotti, F; Reni, M; Falconi, M.

In: European Journal of Surgical Oncology, Vol. 44, No. 1, 2018, p. 24-30.

Research output: Contribution to journalArticle

@article{b1718c502dd446ab9c270dc484cf58ae,
title = "Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer",
abstract = "Background: Identification of factors associated with dismal survival after surgery in resectable pancreatic ductal adenocarcinoma is important to select patients for neoadjuvant treatment. The present meta-analysis aimed to compare the results of distal pancreatectomy for resectable adenocarcinoma of the pancreatic body-tail with and without splenic vessels infiltration. Methods: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines. The inclusion criteria were studies including patients who underwent distal pancreatectomy for pancreatic cancer with or without splenic vessels infiltration. 5-year overall survival (OS) was the primary outcomes. Meta-analysis was carried out applying time-to-event method. Results: Six articles with 423 patients were analysed. Patients with pathological splenic artery invasion had a worse survival compared with those without infiltration (Hazard ratio 1.76, 95{\%} CI 1.36-2.28; P < 0.0001). A similar results was found when considering pathological splenic vessels infiltration, showing that survival was significantly poorer when splenic vein infiltration was present (Hazard ratio 1.51, 95{\%} CI 1.19-1.93; P = 0.0009). Conclusions: This meta-analysis showed worse survival for patients with splenic vessels infiltration undergoing distal pancreatectomy for pancreatic cancer. Splenic vessels infiltration represents the stigmata of a more aggressive disease, although resectable. {\circledC} 2017 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology.",
author = "S Crippa and Roberto Cirocchi and P Maisonneuve and S Partelli and I Pergolini and D Tamburrino and F Aleotti and M Reni and M Falconi",
year = "2018",
doi = "10.1016/j.ejso.2017.10.217",
language = "English",
volume = "44",
pages = "24--30",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer

AU - Crippa, S

AU - Cirocchi, Roberto

AU - Maisonneuve, P

AU - Partelli, S

AU - Pergolini, I

AU - Tamburrino, D

AU - Aleotti, F

AU - Reni, M

AU - Falconi, M

PY - 2018

Y1 - 2018

N2 - Background: Identification of factors associated with dismal survival after surgery in resectable pancreatic ductal adenocarcinoma is important to select patients for neoadjuvant treatment. The present meta-analysis aimed to compare the results of distal pancreatectomy for resectable adenocarcinoma of the pancreatic body-tail with and without splenic vessels infiltration. Methods: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines. The inclusion criteria were studies including patients who underwent distal pancreatectomy for pancreatic cancer with or without splenic vessels infiltration. 5-year overall survival (OS) was the primary outcomes. Meta-analysis was carried out applying time-to-event method. Results: Six articles with 423 patients were analysed. Patients with pathological splenic artery invasion had a worse survival compared with those without infiltration (Hazard ratio 1.76, 95% CI 1.36-2.28; P < 0.0001). A similar results was found when considering pathological splenic vessels infiltration, showing that survival was significantly poorer when splenic vein infiltration was present (Hazard ratio 1.51, 95% CI 1.19-1.93; P = 0.0009). Conclusions: This meta-analysis showed worse survival for patients with splenic vessels infiltration undergoing distal pancreatectomy for pancreatic cancer. Splenic vessels infiltration represents the stigmata of a more aggressive disease, although resectable. © 2017 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology.

AB - Background: Identification of factors associated with dismal survival after surgery in resectable pancreatic ductal adenocarcinoma is important to select patients for neoadjuvant treatment. The present meta-analysis aimed to compare the results of distal pancreatectomy for resectable adenocarcinoma of the pancreatic body-tail with and without splenic vessels infiltration. Methods: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines. The inclusion criteria were studies including patients who underwent distal pancreatectomy for pancreatic cancer with or without splenic vessels infiltration. 5-year overall survival (OS) was the primary outcomes. Meta-analysis was carried out applying time-to-event method. Results: Six articles with 423 patients were analysed. Patients with pathological splenic artery invasion had a worse survival compared with those without infiltration (Hazard ratio 1.76, 95% CI 1.36-2.28; P < 0.0001). A similar results was found when considering pathological splenic vessels infiltration, showing that survival was significantly poorer when splenic vein infiltration was present (Hazard ratio 1.51, 95% CI 1.19-1.93; P = 0.0009). Conclusions: This meta-analysis showed worse survival for patients with splenic vessels infiltration undergoing distal pancreatectomy for pancreatic cancer. Splenic vessels infiltration represents the stigmata of a more aggressive disease, although resectable. © 2017 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology.

U2 - 10.1016/j.ejso.2017.10.217

DO - 10.1016/j.ejso.2017.10.217

M3 - Article

VL - 44

SP - 24

EP - 30

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -